Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329645 | 0.86 | NAMPT (0.38) | MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6337169 | 0.86 | NPC1 (0.45) | TAAR1NPC1RAB9AGAAMAPT | |
| SCHEMBL6177232 | 0.85 | TAAR1 (0.48) | TAAR1NPC1RAB9AGAAMAPT | |
| SCHEMBL6339222 | 0.81 | RAB9A (0.44) | TAAR1NPC1RAB9AGAAMAPT | |
| SCHEMBL6328159 | 0.79 | MGLL (0.46) | TAAR1NPC1RAB9AGAAMAPT | |
| SCHEMBL6176742 | 0.79 | TAAR1 (0.47) | TAAR1NPC1RAB9AGAAMAPT | |
| SCHEMBL6331723 | 0.76 | CA2 (0.48) | MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6336505 | 0.73 | NAMPT (0.43) | L3MBTL1 | |
| SCHEMBL6176352 | 0.73 | ALDH1A1 (0.44) | NPC1RAB9AGAAMAPTSMN1; SMN2 | |
| SCHEMBL4874807 | 0.70 | AKT1 (0.42) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956050-B2 | Imidazole compounds as anti-inflammatory and analgesic agents | PFIZER, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | HIRANO MISATO (JP) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, PTGES | TAAR1 2861/4885NPC1 959/4885RAB9A 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.